1. Volume 144, Issue 1, Pages 46-50 (January 2017)
Combination therapy with topotecan, paclitaxel, and bevacizumab improves progression-free survival in recurrent small cell neuroendocrine carcinoma of the cervix 
M. Frumovitz, M.F. Munsell, J.K. Burzawa, L.A. Byers, P. Ramalingam, J. Brown, R.L. Coleman 
Gynecologic Oncology 
Volume 144, Issue 1, Pages (January 2017)
DOI: /j.ygyno
Copyright © 2016 Elsevier Inc. Terms and Conditions

2. Fig. 1
Progression-free survival in patients with small cell cervix cancer treated with topotecan, paclitaxel, and bevacizumab (TPB) or only with non-TPB regimens as primary therapy for first recurrence.
Gynecologic Oncology  , 46-50DOI: ( /j.ygyno )
Copyright © 2016 Elsevier Inc. Terms and Conditions

3. Fig. 2
Overall survival in patients with small cell cervix cancer treated with topotecan, paclitaxel, and bevacizumab (TPB) or only with non-TPB regimens as primary therapy for first recurrence.
Gynecologic Oncology  , 46-50DOI: ( /j.ygyno )
Copyright © 2016 Elsevier Inc. Terms and Conditions